The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070.
Novel methods for the treatment of inflammatory and autoimmune diseases comprising the administration of salt-inducible kinase inhibitors are claimed. One novel inhibitor (HG-9-91-01) and the use of 2,4-diaminopyrimidine and 2,6-diaminopyrimidine derivatives are claimed. The use of such inhibitors upregulates the level of the anti-inflammatory cytokine IL-10 in macrophages.